Recce Pharmaceuticals Ltd (RCE.AX)
| Previous close | 0.5150 |
| Open | 0.5000 |
| Bid | 0.5000 x 55200 |
| Ask | 0.5300 x 1644700 |
| Day's range | 0.4950 - 0.5320 |
| 52-week range | 0.4100 - 0.7772 |
| Volume | |
| Avg. volume | 153,257 |
| Market cap | 108.095M |
| Beta (5Y monthly) | 1.27 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0600 |
| Earnings date | 27 Feb 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireRecce Pharmaceuticals Completes 5,000 RECCE® 327 Doses a Week under Good Manufacturing Practice (GMP)
Successful production of 5,000 x RECCE® 327 (R327) doses per week under Good Manufacturing Practises (GMP) campaignR327 manufactured under GMP standards in support of current and anticipated clinical trials, demonstrating compliance with guidelines set by regulatory authorities, such as the U.S. Food and Drug Administration (FDA) SYDNEY, Australia, April 17, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd. (ASX: RCE, FSE: R9Q), (the Company), the Company developing a new class of synthetic an
- GlobeNewswire
Recce Pharmaceuticals Provides Business Update
Promising Minimum Inhibitory Concentration (MIC) activity in Phase I/II trial for urinary tract infections (UTI) and urosepsis with an increase in dosage expected to begin in the next several weeksExpansion of Phase I/II trial for diabetic foot infections (DFI) with efficacy achieved and now moving towards the initiation of a Phase III registrational trial in Indonesia scheduled to commence in Q3 2024RECCE® 327 (R327) shown to be effective against more than 300 strains of bacterial pathogens dur
- GlobeNewswire
Recce Pharmaceuticals Selected by UK Government Innovation Agency to Participate in AMR Mission 2024
Recce recognized by the United Kingdom Government Innovation Agency among the most promising organizations for the UK AMR Inward Mission 2024Recce chosen as one of 18 organizations globally for its potential to tackle the global health threat of AMR and superbugsProfessor Dame Sally Davies, former England Chief Medical Officer, hosting a reception with selected organizations offering Recce strategic partnering opportunities in the AMR space SYDNEY, Australia, April 09, 2024 (GLOBE NEWSWIRE) -- R
